6505--Hydroxychloroquine SO4 Tablets
ID: 36E79725R0022Type: Presolicitation
AwardedJul 15, 2025
$14.6M$14,563,769
AwardeeBRYANT RANCH PREPACK BURBANK 91504
Award #:36E79725D0039
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/6a60797d7d15409792dedbbb59d9d510/view
Timeline
    Description

    The Department of Veterans Affairs is soliciting offers for the procurement of Hydroxychloroquine SO4 Tablets, specifically 200mg tablets, through its National Acquisition Center. The solicitation outlines the requirements for supply contracts, including compliance with Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), as well as the need for a unique National Drug Code (NDC) for each product. This procurement is crucial for ensuring a consistent supply of pharmaceuticals to government healthcare facilities, thereby maintaining availability and pricing stability. Interested contractors should note that the deadline for submitting offers has been extended to April 8, 2025, at 2:30 PM CDT, and can reach out to Contract Specialist Christopher Carthron at Christopher.Carthron@va.gov for further inquiries.

    Point(s) of Contact
    Chris CarthronContracting Officer
    (708) 786-4980
    Christopher.Carthron@va.gov
    Files
    Title
    Posted
    36E79725R0022_1.docx
    The document outlines a solicitation for pharmaceutical supplies by the Department of Veterans Affairs (VA) under the National Acquisition Center. The RFP delineates the requirements for supply contracts specifically for Hydroxychloroquine SO4 200mg tablets in two configurations, detailing quantities and pricing for the base year and four options. Submission criteria include providing a unique National Drug Code (NDC) for each product, compliance with manufacturing standards, and appropriate regulatory documentation. The solicitation specifies the length of the contract, implementation periods, and the structure for pricing, which includes a 0.5% Cost Recovery Fee. Contractors are required to have acceptable Good Manufacturing Practices (cGMP) status with the FDA, and also adhere to the Drug Supply Chain Security Act (DSCSA) for serialization and tracking. Performance will be evaluated based on timely delivery and compliance with contract terms. This procurement aims to secure a consistent supply of pharmaceuticals for various government healthcare facilities, ensuring both availability and pricing stability within compliance frameworks. The document emphasizes adherence to regulations and the integration of efficient supply chain practices for government entities.
    36E79725R0022_2.docx
    The Department of Veterans Affairs (VA) is issuing a Request for Proposal (RFP) 36E79725R0022 for an unrestricted procurement of Hydroxychloroquine SO4 Tablets. This procurement serves various federal entities, including the Department of Defense, Bureau of Prisons, and Indian Health Service. The contract period spans one year with four optional one-year extensions, aimed at ensuring a continuous supply of the drug. Offerors must provide their unique National Drug Code (NDC) without labeling over existing labels. The solicitation will be available electronically on or around March 12, 2025, with submissions due by March 26, 2025. The estimated annual requirements total 163,395 bottles of 100-count and 25,853 bottles of 500-count Hydroxychloroquine tablets. Interested parties must monitor SAM.gov for updates and communicate with the contracting officer, Chris Carthron, for inquiries. This RFP reflects the VA's ongoing efforts to secure essential medications for veteran and federal healthcare programs.
    36E79725R0022 0001.docx
    The document is an amendment to solicitation number 36E79725R0022 issued by the Department of Veterans Affairs, specifically the National Acquisition Center. The primary purpose of this amendment is to extend the deadline for offers concerning Hydroxychloroquine SO4 200MG Tabs. The new due date is set for April 8, 2025, at 2:30 PM CDT, an extension from the previous deadline of April 1, 2025. All other terms and conditions of the original solicitation remain unchanged. The document is formally signed by Christopher Carthron, the contracting officer, who oversees the amendment process. This amendment underscores the importance of timely communication to bidders and sets clear expectations regarding offer submissions in a federal procurement context.
    Lifecycle
    Title
    Type
    6505--Hydroxychloroquine Tablets
    Award
    6505--Hydroxychloroquine SO4 Tablets
    Solicitation
    6505--Hydroxychloroquine SO4 Tablets
    Currently viewing
    Presolicitation
    Similar Opportunities
    6505--Ustekinumab Pens/Syringes or Biosimilar
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Ustekinumab Pens/Syringes or Biosimilars, aimed at supplying various federal health entities including the Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract will be awarded for an initial period of one year, with the possibility of four additional one-year option periods, ensuring a consistent supply of these critical pharmaceutical products through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must provide drugs with unique National Drug Code (NDC) numbers and ensure that any biosimilar products meet FDA licensing requirements, as outlined in the FDA Purple Book. The solicitation is expected to be released around January 12, 2026, with a tentative closing date of January 27, 2026; interested parties should direct inquiries to Chris Carthron at Christopher.Carthron@va.gov or (708) 786-4980.
    6505--Zonisamide Capsules
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified suppliers for a Firm Fixed Price, Indefinite-Delivery Requirements contract for Zonisamide Capsules in 25mg, 50mg, and 100mg dosages. Offerors are required to provide pricing for a base year and four option years, submit a 0.5% Cost Recovery Fee, and comply with stringent packaging and barcoding standards, including adherence to the Drug Supply Chain Security Act (DSCSA) and National Drug Code (NDC) requirements. These pharmaceutical products are crucial for the healthcare services provided to veterans and military personnel through the VA and DoD Pharmaceutical Prime Vendor Programs. Interested parties should contact Contract Specialist Christopher Carthron at Christopher.Carthron@va.gov for further details, and ensure they meet all compliance and registration requirements, including current SAM registration.
    COLESTIPOL HCL 1GM TAB and DESONIDE 0.05% CREAM - 762 TUCSON
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is conducting a Sources Sought Notice to identify potential qualified domestic sources for the procurement of COLESTIPOL HCL 1GM TAB and DESONIDE 0.05% CREAM through its National CMOP Office. This announcement serves as a market research tool rather than a solicitation, aiming to gather information on vendors' capabilities to meet the requirements outlined in the Statement of Requirements. The products sought are critical for pharmaceutical preparation and will support the healthcare needs of veterans. Interested vendors must submit their responses, including company details and capability statements, via email to Jennifer Coleman at Jennifer.Coleman4@va.gov by December 19, 2025, at 3:00 PM CDT. This notice does not obligate the VA to issue a solicitation.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    6505--LEVOFLOXICIN 750MG / DEXTROSE 5% 150ML, IVPB (VA-26-00008212)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking small business vendors to supply LEVOFLOXICIN 750MG / DEXTROSE 5% 150ML, IVPB, as part of solicitation number 36C77026Q0005. This procurement involves delivering a total of 1,460 boxes of the pharmaceutical product to the VA CMOP facility in Hines, Illinois, with a base period and four option years, each requiring delivery by January 5th of the respective year. The goods are critical for patient care within the VA healthcare system, emphasizing the importance of timely and compliant delivery. Interested vendors must submit their proposals, including a signed SF 1449, pricing schedule, and other required documentation, by December 16, 2025, at 3 PM Central Time, and can direct inquiries to Contract Specialist Jennifer Coleman at Jennifer.Coleman4@va.gov.
    Pharmaceutical Repackaging Services for National CMOP (770)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for pharmaceutical repackaging services for the National Consolidated Mail Outpatient Pharmacy (CMOP) program. The contract, identified as 36C77026R0004, is a firm-fixed-price, indefinite-delivery agreement intended to support the repackaging of government-purchased oral solid pharmaceuticals into various bottle sizes for distribution to over 7 million veterans. The contract spans a five-year ordering period from February 1, 2026, to January 31, 2031, with a potential six-month extension, and has a minimum value of $20 million and a maximum value of $125 million. Interested contractors should contact Renee Kreutzer at renee.kreutzer@va.gov for further details and must submit their proposals by the specified deadlines, ensuring compliance with all relevant regulations and standards.
    760-25-1-050-0154 -Leavenworth CMOP THYROID TABLETS -(VA-25-00022614)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for the procurement of Armour Thyroid tablets for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) under solicitation number 36C77025Q0079. This Request for Quotation (RFQ) emphasizes the need for specific brand-name pharmaceuticals, with a focus on compliance with federal regulations, including the Drug Supply Chain Security Act and the Buy American Act. The procurement process aims to ensure a reliable supply of essential medications for veterans, with a firm-fixed-price contract expected to be awarded based on fair market evaluations. Interested vendors must submit their quotes by December 27, 2024, at 4:00 PM CST, and can direct inquiries to Jennifer L. Knight at jennifer.knight@va.gov or by phone at 913-684-0162.
    Ondansetron Orally Disintegrating Tablets
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Ondansetron Orally Disintegrating Tablets (ODT), specifically 4 MG and 8 MG tablets in various count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are critical for treating nausea and vomiting in patients, and will be available for purchase by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in September 2025, although the DLA reserves the right to issue it earlier or later. Interested parties should direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or call 445-737-0713, and are encouraged to set up automated notifications for any changes to the solicitation through the DLA Bid Board System and Sam.Gov.
    Metformin HCL
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.